COVID-19 in-hospital mortality and mode of death in a dynamic and non-restricted tertiary care model in Germany

Siegbert Rieg¹, Maja von Cube², Johannes Kalbhenn³, Stefan Utzolino⁴, Katharina Pernice⁵, Lena Bechet¹, Johanna Baur^{6,7}, Corinna N. Lang^{6,7}, Dirk Wagner¹, Martin Wolkewitz², Winfried V. Kern¹, Paul Biever^{6,7}; on behalf of the COVID UKF Study Group

¹ Division of Infectious Diseases, Department of Medicine II, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany

² Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, 79104 Freiburg, Germany

³ Department of Anesthesiology and Intensive Care Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany

⁴ Department of General and Visceral Surgery, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany

⁵ Department of Cardiovascular Surgery, Heart Center, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany

⁶ Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany

⁷ Department of Cardiology and Angiology I, Heart Center Freiburg University, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany

with linked authorship to members in the Acknowledgements: COVID UKF Study Group: Gabriele Peyerl-Hoffmann, Stephan Horn, Daniel Hornuss, Katharina Laubner, Dominik Bettinger, Christoph Jäger, Eric Peter Prager, Viviane Zotzmann, Dawid L. Staudacher, Cornelius Waller, Hans Fuchs, Sebastian Fähndrich, Marcus Panning, Hans-Jörg Busch, Monika Engelhardt, Hartmut Bürkle, Michael Berchtold-Herz, Thorsten Hammer, Felix Hans, Hartmut Hengel, Peter Hasselblatt, Wolfgang Kühn, Daniel Duerschmied, Robert Thimme, Christoph Bode, Hajo Grundmann, Philipp Henneke

Keywords: SARS-CoV-2, mortality, cause of death, complications, multistate model, extracorporeal membrane-oxygenation, acute respiratory distress syndrome (ARDS)

*Corresponding author

Siegbert Rieg, MD, DTMH
Division of Infectious Diseases, Department of Medicine II
Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
Hugstetter Straße 55, D-79106 Freiburg, Germany
Phone +49-761-270 18190
Fax +49-761-270 18200
E-mail: siegbert.rieg@uniklinik-freiburg.de

40 Abstract

41

42 Background

43 Reported mortality of hospitalised COVID-19 patients varies substantially, particularly in critically ill
44 patients. So far COVID-19 in-hospital mortality and modes of death under optimised care conditions
45 have not been systematically studied.

46 Methods

47 This retrospective observational monocenter cohort study was performed after implementation of a
48 non-restricted, dynamic tertiary care model at the University Medical Center Freiburg, an
49 experienced ARDS and ECMO referral center. All hospitalised patients with PCR-confirmed SARS-CoV-
50 2 infection were included. The primary endpoint was in-hospital mortality, secondary endpoints
51 included major complications and modes of death. A multistate analysis and a Cox regression analysis
52 for competing risk models were performed. Modes of death were determined by two independent
53 reviewers.

54 Results

55 Between February 25, and May 8, 213 patients were included in the analysis. The median age was 65
56 years, 129 patients (61%) were male. 70 patients (33%) were admitted to the intensive care unit
57 (ICU), of which 57 patients (81%) received mechanical ventilation and 23 patients (33%)
58 extracorporeal membrane-oxygenation (ECMO) support. According to the multistate model the
59 probability to die within 90 days after COVID-19 onset was 24% in the whole cohort. If the levels of
60 care at time of study entry were accounted for, the probabilities to die were 16% if the patient was
61 initially on a regular ward, 47% if in the ICU and 57% if mechanical ventilation was required at study
62 entry. Age ≥ 65 years and male sex were predictors for in-hospital death. Predominant complications
63 – as judged by two independent reviewers – determining modes of death were multi-organ failure,
64 septic shock and thromboembolic and hemorrhagic complications.

65 Conclusion

66 In a dynamic care model COVID-19-related in-hospital mortality remained substantial. In the absence
67 of potent antiviral agents, strategies to alleviate or prevent the identified complications should be
68 investigated. In this context, multistate analyses enable comparison of models-of-care and treatment
69 strategies and allow estimation and allocation of health care resources.

70

71 Registration

72 German Clinical Trials Register (identifier DRKS00021775), retrospectively registered June 10, 2020.

73

74 Background

75 The current SARS-CoV-2 pandemic is a public health emergency of international concern, which
 76 poses immense challenges on health care systems (1). Although modulated by host factors like age
 77 and comorbidities, overall about 10-15% of SARS-Cov-2 infected patients require hospitalisation and
 78 20-30% of hospitalised patients develop critical or life-threatening COVID-19 manifestations (2).
 79 Reported mortality rates of COVID-19 patients are in the range of 20-40% (1;3-5) for hospitalised
 80 patients and 30-88% for critically-ill or ICU patients with substantial differences between countries
 81 and regions (3-10). Several reasons may account for the observed wide range of these estimates.
 82 Referral strategies to the hospital may differ. A high local COVID-19 incidence may put pressure on
 83 health care systems leading to restrictions in care with the need to triage patients, and possibly
 84 results in high numbers of infected health care workers. Moreover, intensive care unit (ICU) and
 85 therefore ventilation and extracorporeal membrane-oxygenation (ECMO) capacities may
 86 substantially vary, which may influence e.g. admission strategies and decisions on treatment
 87 withdrawal.

88 Compared to neighbouring countries, in Germany the SARS-CoV-2 pandemic started later, with single
 89 cases at the end of February. This delay provided the health care system and particularly the
 90 inpatient sector with valuable time to prepare for a rising case load, and therefore allowed to avoid
 91 inpatient bed and ICU capacity shortages. The Freiburg University Medical Center, a center with
 92 profound expertise in ARDS treatment and ECMO support, formed a Coronavirus task force at the
 93 end of January 2020. In the following weeks a COVID-19 dynamic care model was developed and
 94 implemented. These preparations together with a relatively high SARS-CoV-2 testing capacity and
 95 early lock-down strategies in Germany yielded a situation, in which regional treatment capacities
 96 were sufficient at any stage of the pandemic and at any level of care despite a regional COVID-19
 97 peak incidence of 120 cases/100.000 inhabitants per week at the beginning of April.

98 We hypothesised that this constitutes a unique opportunity to study the COVID-19-related morbidity
 99 and mortality in patients requiring hospitalisation in a setting of non-restricted care. Here we briefly
 100 outline the implemented dynamic care model and summarise the corresponding outcomes. Specific
 101 aims of the study are i.) to assess COVID-19-related in-hospital mortality in a dynamic and non-
 102 restricted care model at an ARDS and ECMO referral center; ii.) to define major complications and
 103 modes of death in a setting of extended care with maximum supportive therapy; and iii.) to
 104 propagate and stimulate reporting of clinical studies in COVID-19 research using multistate models.

105

106 Methods

107 *Study design, setting and participants*

The current study constitutes a *post hoc* analysis of data collected within a retrospective cohort study conducted at the University Medical Center Freiburg. This 1,600-bed tertiary care institution serves the southwest region of the German state of Baden-Württemberg and is one of the largest ARDS and ECMO referral centers in Germany. All hospitalised patients with detection of SARS-CoV-2 using PCR in a respiratory sample between February 25 and May 8, 2020 were eligible and included. The last day of follow-up that was included was June 19.

Beginning in January 2020 the Coronavirus task force at the University Medical Center Freiburg developed a dynamic care model for COVID-19 patients (outlined in **Supplementary Figure S1**). Patients were treated on COVID-19 regular wards, COVID-19 intermediate care and intensive care units (ICU) run by different departments. Patients were followed during their hospital stay by Infectious Diseases (ID) physicians performing daily COVID-19 rounds or being involved via the ID consultation service. The measures implemented in the COVID-19 response, the evolution of the peak incidences in the region and the corresponding number of admissions in our center are shown in **Supplementary Figure S2**.

Variables collected and definitions

Demographic variables, comorbidities, diagnostic procedures and data on treatment modalities, complications and outcome were extracted by reviewing the admission, transfer and discharge reports and the electronic patient record. Patients were followed until hospital discharge or death.

Comorbidities were recorded in the following eight categories: lung disease (COPD or other chronic pulmonary disease), heart disease (coronary artery disease/ischemic cardiomyopathy or heart failure NYHA II-IV), diabetes mellitus, chronic liver disease (Child B or C), active malignancy, primary or secondary immunodeficiency (the latter being immunosuppressive drugs incl. corticosteroids of $\geq 20\text{mg/day}$ prednisolone-equivalent), obesity (body mass index [BMI] $>30\text{kg/m}^2$) and neurological disease (dementia, stroke or Parkinson's disease). For Cox regression analysis patients were divided into the groups 'no comorbidity' and 'at least one comorbidity' present. Hospital-acquired COVID-19 was assumed in the setting of prolonged hospitalisation and if contact tracing yielded contact with other COVID-19 patients or health-care workers in the hospital as the only relevant exposure.

A thorough case review by two independent investigators (intensivists [ICU patients] or ID physicians) concerning complications and modes of death was performed for all patients. All discrepancies between the two reviewers were reviewed and resulted in an additional assessment by a third investigator in order to obtain a final decision. A detailed documentation of this review process is outlined in **Supplementary Table 1**.

Classification of ARDS severity was performed according to the Berlin Definition (11). Indication for ECMO support was in accordance with the guidelines of the Extracorporeal Life Support Organization (ELSO) (12) and did not deviate from usual indications. Multi-organ failure (MOF) was defined as combination of two or more severe organ system dysfunctions. Predominant terminal organ failure during dying process was defined as severe organ dysfunction that either resulted directly in patient's death or in withdrawal of life support. Concerning the categories 'Life support in dying process' and 'Involvement of COVID-19', patients were allocated to one category. Reviewers designated each death to ,related to COVID-19' or ,unrelated to COVID-19'.

Ethical consideration

The study and data collection were approved by the Institutional Review Board of the University Medical Center Freiburg (348/20) and was registered in the German Clinical Trials Register (identifier DRKS00021775). We followed the ethical standards set by the Helsinki Declaration of 1964, as revised in 2013, and the research guidelines of the University of Freiburg. The Institutional Review Board of the University Medical Center Freiburg considered the collection of routine data as evaluation of service and waived the need for written informed consent.

Statistical analysis

The primary endpoint was in-hospital mortality. Secondary endpoints included major complications and modes of death. Baseline epidemiological and clinical characteristics, complications and outcomes of patients with and without ICU stay were compared using the t-test or Mann-Whitney-U-test for continuous variables and the χ^2 test or Fisher's exact test for categorical variables.

We performed a multistate analysis to investigate the mean length of hospitalisation, the mean duration of mechanical ventilation (MV) and ECMO as well as the risks of death and discharge. The model is shown in **Supplementary Figure S3**. The multistate model accounts for the states hospitalisation in a 'regular ward', 'ICU', 'MV', 'ECMO' as well as 'discharge alive' and 'death'. Patients entered the study at the time of hospitalisation due to COVID-19 or at the time of a positive SARS-CoV-2-PCR (in hospital-acquired COVID-19 cases) and were under observation until discharge or death. We accounted for the fact, that some patients were directly admitted to the ICU either with or without MV. A patient requiring ECMO was defined to have at least 0.5 days of MV beforehand and (in case the patient did not die under ECMO) afterwards.

For the risk factor analysis, we used a competing risks model to study effects on the time from hospitalisation to death in the hospital. In this model, the different states of hospitalisation (regular ward, ICU, MV, ECMO) were not differentiated. First, we estimated cause-specific hazard ratios for death and discharge. These gave information on both direct and indirect effects on the risk of in-hospital death. Then, we estimated the subdistribution hazard ratio of death, which quantifies the

effect of risk factors on the absolute risks (rather than the rates) thereby combining the direct and indirect effects found in the cause-specific analysis. Statistical significance was determined at $p < 0.05$. All analyses were performed with R studio Version 1.2.5033.

Results

Epidemiological and clinical characteristics

A total of 213 COVID patients were included in the study (**Table 1**). The median age was 65 years, 129 patients (61%) were male. Fifty cases (23%) were considered to be hospital-acquired infections. While 56 patients (26%) were without significant comorbidities, 79 patients (37%) reported one, and 78 patients (37%) two or more comorbidities, with coronary artery disease/ischemic cardiomyopathy (21%), diabetes mellitus (20%) and obesity ($BMI > 30 \text{ mg/m}^2$, 24%) being the most prevalent diseases. The median time from onset of symptoms to hospitalisation was 6 days. Overall 27 patients (13%) were ICU-referrals from regional hospitals due to complex respiratory or ARDS management and/or the need of ECMO support. During hospitalisation 70 patients (33%) were admitted to the ICU (median SAPS2-score of 46, median Horovitz-index on day 1 of ICU admission 110), of which 57 patients (81%) received invasive MV (median duration 17 days), and 23 patients (33%) needed ECMO support (median duration 11 days, range 1-68 days) (**Table 2**). Medical treatment included lopinavir/ritonavir (54 patients), hydroxychloroquine (92 patients), and remdesivir (1 patient). Seven patients received tocilizumab. 161 out of 213 patients were discharged alive and 51 patients died. Of the latter, 32 deaths occurred in the ICU (one death after ICU discharge) and 18 deaths on regular wards. At the end of follow-up, one patient, though recovered from COVID-19, was still hospitalised on a regular ward for treatment of an underlying malignancy.

Multistate model analysis

Considering all 213 patients in the described dynamic tertiary care model, the population averaged probability to have died 90 days after hospitalisation with COVID-19 was 23.9%. The chance for being discharged alive was 75,6%. There was a 0.5% chance to still be in the hospital after 90 days. A stacked probability plot illustrating the probabilities of COVID-19 patients to be in specific states (regular ward, ICU, MV, ECMO, discharged alive or dead) over the course of time is depicted in **Figure 1**. Moreover, the plot illustrates the population averaged mean duration spent in each state/level of care. These correspond to the coloured area between two curves.

By accounting for the levels of care when entering the study, i.e. regular ward, ICU, MV, the multistate model allows for an estimation of the approximate length of hospital stay and the probability to be discharged alive or to die at different levels of care. A patient that was first

admitted to a regular ward stayed on average 13.6 days in the hospital, 0.8 days in the ICU, 1.4 days with MV and 0.2 days with MV and ECMO within a total stay of 90 days (**Figure 2 and Supplementary Figure S4**). The probability to be discharged alive for patients starting in the ,regular ward'-state was 83%, the probability to die was 16%. In contrast, a patient that was admitted to the ICU needed 21.5 days in the ICU, 13.9 days of these with MV and 2.0 days with ECMO. The probability to be discharged alive in the following 90 days was 52%, the probability to die was 47%. Patients that directly required MV stayed 23.6 days on MV, and 8.0 days of these with ECMO. Once MV was no longer required, the patient stayed on average 2.4 more days in the ICU and another 4.0 days on the regular ward. The chances to be discharged alive were only 42%.

Multivariable cause-specific Cox regression analysis

The multivariable regression analysis constitutes a competing risks model with the endpoint in-hospital death and the competing risk discharge alive. According to the cause-specific Cox regression older patients have a higher death hazard (HR 3.45, 95% CI 1.49-7.98, for patients 65-74 years of age, and HR 3.56, 95% CI 1.74-7.30 for ≥ 75 years-aged patients). Additionally, we found that the discharge hazard is significantly decreased for males (HR 0.68, 95% CI 0.50-0.94) (**Table 3**). A higher number of comorbid conditions was not significantly associated with altered death or discharge hazards.

In the Fine and Gray model yielding subdistribution hazard ratios, the probability to die was significantly increased for males (HR 1.90, 95% CI 1.04-3.48) and patients aged 65 years or older (HR 4.16, 95% CI 1.82-9.49 for age group 65-74 years, and HR 4.13, 95% CI 2.05-8.32 for ≥ 75 years of age). For males the decreased discharge hazard leads to a prolonged length of stay and therefore increased the risk of death in the hospital. The increased death risk for patients older than 65 is explained by a direct effect on the death hazard. Stacked probability plots (**Supplementary Figures S5-S9**) stratified respectively by age, sex, the presence of comorbidities, immunodeficiency and malignancy/neoplasm illustrate in detail the effect of these risk factors not only on mortality, but also on the six states of the multistate model.

Complications and presumed modes of death

According to the individual case review, ICU patients (both, survivors and non-survivors) suffered from a multitude of complications (**Table 2**), the four dominant ones being septic shock in 43 patients (61%), acute kidney injury with the need for renal replacement therapy in 26 of 70 patients (37%), as well as thromboembolic and hemorrhagic complications. Pulmonary embolism was diagnosed in 16 patients (23%). Replacement of extracorporeal devices due to thrombosis had to be performed in 11 of 26 patients (42%) on renal replacement therapy and 12 of 23 patients (52%) on ECMO. Ischemic

stroke occurred in 9 of 70 patients (13%). Major hemorrhagic manifestations were intracerebral bleeding in 11 patients (16%) and pulmonary hemorrhage in 8 patients (11%).

As of June 19, 2020, 18 patients died on regular wards. The median age of these patients was 80 years – in accordance to the patients’ will, ICU transfer/treatment and MV was withheld in these patients. Death was due to respiratory failure in 12 patients and multi-organ failure in 6 patients.

All but four patients that received ICU care succumbed due to multi-organ failure (**Tables 2 and 4**). A median of three organ systems were involved with lung failure (32 patients), kidney/renal failure (24 patients), brain injury (17 patients), heart failure (14 patients) and gastrointestinal injury (13 patients, in particular acute mesenteric ischemia) being the predominant terminal organ failures involved. In 21 of 33 patients (63%) septic shock was a critical complication considered to be relevant for multi-organ failure and death.

Of 51 patients that died, death was presumed to be secondary to COVID-19 in 30 patients with frailty/comorbidities. Sixteen patients (31%) without relevant comorbidities, i.e. without underlying diseases impacting on life expectancy, died due to COVID-19 or COVID-19-related complications. Time points of death are depicted in the cohort plot in **Supplementary Figure S4**.

Discussion

The principal findings of this study are as follows. i.) In the implemented care model yielding non-restricted conditions at an experienced ARDS and ECMO referral center, COVID-19-related in-hospital-mortality remained high at around 25%. ii.) Older age and male sex were independent risk factors for death. iii) In patients requiring ICU care, 1 out of 2 patients died with critical events being lung and multi-organ failure, septic shock, and thromboembolic and hemorrhagic complications. iv.) In the setting of a referral center the average length of stay in the hospital for COVID-19 patients was 16 days if admittance was to a regular ward, 26.5 days for patients admitted to the ICU, and 30 days in the case of initial MV in hospital. In the latter group 11 days of ECMO support were required.

In the ongoing SARS-CoV-2 pandemic solid estimates on patient outcomes such as mortality and major complications, and on the required health service resources, are pivotal, yet difficult to generate (13). Although COVID-19 studies are published at unprecedented frequency and speed, comparability of studies is hampered by the use of different study designs, varying standards of reporting and the statistical approaches used. So far, the majority of studies, particularly those in critically-ill or ICU patients, reported on preliminary in-hospital mortality rates, as 23-72% of patients were still hospitalised at the time of reporting (5;7-10).

We believe our study provides superior estimates on mortality, complications and length of stay, as different study set up and analytical approaches compared to previous studies were employed. First, by implementing a dynamic care model, we excluded that the need to triage patients, or the availability of limited ICU capacities impacted on mortality rate in a major way. Moreover, given the experience of a large interdisciplinary ARDS and ECMO referral center together with a highly active ID service, the conditions to manage critically ill COVID-19 patients with severe pneumonia and development of ARDS adhered to highest international standards. However, the COVID-19 related in-hospital mortality rate of 24% overall, of 47% in the ICU subgroup and of 57% in the MV subgroup remained substantial even under maximal respiratory support with prolonged provision of ECMO and other advanced therapies including prone-positioning. Of note, about one third of patients that died were without relevant comorbidities and were believed to have a normal life expectancy prior to SARS-CoV-2 infection.

The identified risk factors for death, namely age and male sex, are in line with findings of published studies. Interestingly, usage of a competing risk model identified male sex to be associated with a decreased discharge hazard, thereby contributing indirectly to an increased risk of death. Comorbidities were either equally distributed or more often prevalent in the ICU subgroup, with the only exception of immunodeficiency, which was more frequent in the Non-ICU group.

The present study comprises 70 ICU patients, including 23 patients with ECMO support. It is the first study with a completed follow-up, as all patients were discharged from the ICU. The only patient still in hospital has recovered from COVID-19. Importantly, our study provides detailed information on complications and presumed modes of death. This detailed analysis reveals that in the course of prolonged respiratory support a range of serious and outcome-relevant complications arise. The observed pattern with multi-organ failure implicates that COVID-19, at least in critically ill patients, should be regarded as a multi-system disease that reaches far beyond the respiratory tract and severe ARDS. This is in line with recent reports on endothelial cell involvement and diffuse vascular organ changes (14;15). Further investigations including histopathological analysis of organ biopsies (ante- and post-mortem) are needed to elucidate critical organ involvement, as well as underlying pathophysiological mechanisms. The high rate of thromboembolic complications corroborates recent findings in case series and autopsy studies of a pronounced coagulopathy in severe COVID-19 (16-19). The observed high incidence of septic shock possibly contributed to a compromised microcirculation, but may also be a consequence thereof. However, given the severity of COVID-19 in the ICU subgroup (indicated by the high proportion of moderate and severe ARDS, low Horovitz indices and the high rate of complications) it is noteworthy that 1 out of 2 ICU patients could be discharged alive.

In the context of COVID-19 randomised controlled trials cannot be realised for all treatment modalities (pharmacological or supportive). Therefore data of observational studies will need to be analysed and compared (20;21). In the current study we take advantage of a multistate model analysis (22). This approach provides insights into time-dynamic effects and clinical outcomes, avoids common survival biases, and acknowledges active cases by taking into account censoring. In addition to the predicted probabilities for discharge and death, expected average durations in hospital can be calculated for the different states (23). Visualisation using a stacked probability plot provides easy-to-interpret, yet compact and comprehensive information on the patients' clinical progress. This is in line with the proposals of the WHO and the COMET initiative regarding endpoints in clinical COVID-19 studies (24). By applying such a multistate analysis our study provides firm estimates of in-hospital mortality rates and allows a more precise calculation of required ICU and ECMO capacities and therefore allocation of resources in a given care model (25).

Our study has limitations, primarily those inherent to its retrospective observational design. It is a monocenter study, which may limit generalisability. Yet the monocentric design may be considered a prerequisite to study treatment results in a specific care model at an experienced ARDS center. The limited number of patients precluded an analysis of specific treatment strategies, both in terms of antiviral or anti-inflammatory agents and time-sensitive supportive strategies. While the primary endpoint of in-hospital death is reliably determined retrospectively, uncertainties remain in evaluating the mode of death. We tried to minimize this uncertainty by performing individual case review by two independent experienced physicians and explicitly avoiding causal assumptions.

Conclusions

In summary, our study delineates COVID-19-related morbidity and mortality under non-restricted conditions. Thereby research needs that aim to minimize SARS-CoV-2-related complications are identified. By using a multistate model solid estimates for required ICU and ECMO capacities are provided. Finally, this work exemplifies, how best to report on COVID-19 studies to allow for meaningful comparisons of different treatment and care modalities.

List of abbreviations

COVID-19	Coronavirus disease 2019
ECMO	Extracorporeal membrane-oxygenation
ICU	Intensive care unit
BMI	Body mass index BMI
ID	Infectious Diseases
MV	Mechanical ventilation

341 SAPS2-score Simplified acute physiology score 2

342 HR Hazard ratio

343

344 **Declarations**

345 **Ethics approval and consent to participate**

346 The study and data collection were approved by the Institutional Review Board of the University
347 Medical Center Freiburg (348/20) which considered the collection of routine data as evaluation of
348 service and waived the need for written informed consent.

349 **Consent for publication**

350 Not applicable.

351 **Availability of data and materials**

352 The dataset analysed in this study is available from the corresponding author on reasonable request.

353 **Competing interests**

354 All authors declare no competing interests.

355 **Funding**

356 MVC was funded by the EQUIP programme of the Faculty of Medicine, University of Freiburg.

357 **Authors' contributions**

358 SR and PB conceived the study and its design, had full access to the data, and take responsibility for
359 the integrity of the data and accuracy of the analysis. SR, JK, KP, SU, LB, CNL, DW and PB contributed
360 to data collection. MvC performed the primary data analysis. SR, MvC, JK, KP, SU, MW, WVK and PB
361 contributed to data analyses and interpretation. SR and PB drafted the manuscript. All authors
362 critically revised the drafted manuscript and approved its submission.

363 **Acknowledgements**

364 We thank all members of the COVID UKF Study Group who contributed to the development and
365 implementation of the dynamic care model and were involved in patient care, virological diagnostics
366 or infection control: Gabriele Peyerl-Hoffmann, Stephan Horn, Daniel Hornuss, Katharina Laubner,
367 Dominik Bettinger, Christoph Jäger, Eric Peter Prager, Viviane Zotzmann, Dawid L. Staudacher,
368 Cornelius Waller, Hans Fuchs, Sebastian Fähndrich, Hans-Jörg Busch, Monika Engelhardt, Hartmut
369 Bürkle, Michael Berchtold-Herz, Thorsten Hammer, Felix Hans, Marcus Panning, Hartmut Hengel,
370 Peter Hasselblatt, Wolfgang Kühn, Daniel Duerschmied, Robert Thimme, Christoph Bode, Hajo
371 Grundmann, Philipp Henneke.

References

- (1) Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020 March 28;395(10229):1054-62.
- (2) Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis* 2020 June;20(6):669-77.
- (3) Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020 May 22;369:m1985.
- (4) Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ* 2020 May 22;369:m1966.
- (5) Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020 April 22.
- (6) Auld S, Caridi-Scheible M, Blum JM, et al. ICU and ventilator mortality among critically ill adults with COVID-19. *medRxiv* 2020 April 26.
- (7) Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. *N Engl J Med* 2020 May 21;382(21):2012-22.
- (8) Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet* 2020 June 6;395(10239):1763-70.
- (9) Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020 April 6.
- (10) Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020 May;8(5):475-81.
- (11) Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. *JAMA* 2012 June 20;307(23):2526-33.
- (12) Shekar K, Badulak J, Peek G, et al. Extracorporeal Life Support Organization COVID-19 Interim Guidelines. *ASAIO J* 2020 April 29.
- (13) Vincent JL, Taccone FS. Understanding pathways to death in patients with COVID-19. *Lancet Respir Med* 2020 May;8(5):430-2.

406 (14) Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19.
407 Lancet 2020 May 2;395(10234):1417-8.

408 (15) Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction,
409 thrombosis, and dysregulated inflammation. Intensive Care Med 2020 June;46(6):1105-8.

410 (16) Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in
411 anticoagulated severe COVID-19 patients. J Thromb Haemost 2020 April 22.

412 (17) Wichmann D, Sperhake JP, Lutgehetmann M, et al. Autopsy Findings and Venous
413 Thromboembolism in Patients With COVID-19. Ann Intern Med 2020 May 6.

414 (18) Ellul M, Benjamin L, Singh B, et al. Neurological Associations of COVID-19. The Lancet
415 Neurology 2020. doi.org/10.2139/ssrn.3589350.

416 (19) Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients in severe SARS-CoV-
417 2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020 doi:
418 10.1007/s00134-020-06062-x.

419 (20) London AJ, Kimmelman J. Against pandemic research exceptionalism. Science 2020 May
420 1;368(6490):476-7.

421 (21) Shrestha GS, Paneru HR, Vincent JL. Precision medicine for COVID-19: a call for better clinical
422 trials. Crit Care 2020 June 2;24(1):282.

423 (22) Andersen PK, Keiding N. Multi-state models for event history analysis. Stat Methods Med Res
424 2002 April;11(2):91-115.

425 (23) von Cube M, Grodd M, Wolkewitz M, et al. Harmonizing heterogeneous endpoints in COVID-
426 19 trials without loss of information - an essential step to facilitate decision making. medRxiv
427 2020 January 1;2020.

428 (24) Marshall JC, Murthy S, Diaz J, et al.. A minimal common outcome measure set for COVID-19
429 clinical research. The Lancet Infectious Diseases 2020. doi.org/10.1016/S1473-
430 3099(20)30483-7.

431

432 (25) Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources in the
433 Time of Covid-19. N Engl J Med 2020 May 21;382(21):2049-55.

434

435

436 Tables

437 **Table 1:** Epidemiological and clinical characteristics of 213 COVID-19 patients with and without ICU
438 care

Parameter	All patients n=213	Patients with Non-ICU care n=143	Patients with ICU care n=70	p-value
Age	65 (54-79;25)	65 (53-80;27)	65 (59-76;17)	0.86 **
Sex male	129 (61)	77 (54)	52 (74)	0.004 *
Time from clinical onset of symptoms to admission (n=137)	6 (3-9;6)	5 (2-9;7)	7 (4-11;7)	0.04**
NEWS2-Score (n=172)	7 (3-10; 7)	5 (3-8; 5)	10 (8-12; 4)	<0.0001**
Comorbidities				
COPD	13 (6)	6 (4)	7 (10)	0.10*
Coronary artery disease/ischemic cardiomyopathy	45 (21)	29 (20)	16 (23)	0.67*
Malignancy/neoplasm	29 (14)	20 (14)	9 (13)	0.82*
Chemotherapy within last 3 months	9 (4)	6 (4)	3 (4)	0.98*
Primary or secondary immunodeficiency incl. immunosuppressive medication	26 (12)	20 (14)	6 (9)	0.26*
Diabetes mellitus	43/158 (20)	29/92 (20)	14/66 (20)	0.96*
Obesity (BMI >30 kg/m ²)	38 (24)	20 (22)	18 (27)	0.42*
Number of comorbid conditions				
No comorbid condition	56 (26)	38 (27)	18 (26)	0.95*
1 comorbid condition	79 (37)	52 (36)	27 (39)	
≥2 comorbid conditions	78 (37)	53 (37)	25 (36)	
Laboratory investigations on admission				
Lymphocytes [per µl] (n=125)	830 (510-1170; 660)	870 (560-1170; 610)	710 (470-1110; 640)	0.21**
CRP [mg/l] (n=204)	68 (22-134; 112)	36 (12-96; 84)	137 (81-226; 145)	<0.0001**
PCT [ng/ml] (n=182)	0,15 (0,08-0,45; 0,37)	0,11 (0,06-0,19; 0,13)	0,47 (0,21-1,47; 1,26)	<0.0001**
IL-6 [pg/ml] (n=147)	50 (22-146; 124)	32 (16-51; 35)	175 (77-729; 652)	<0.0001**
D-dimers [mg/l FEU] (n=97)	1,4 (0,6-4,6; 4)	1,0 (0,51-1,8; 1,3)	2,3 (1,4-11,9; 10,5)	<0.0001**
Troponin T [ng/ml] (n=127)	16 (7-39; 32)	10 (6-30; 24)	29 (12-61; 49)	0.003**
Medical treatment				
Intravenous antibiotics	131 (62)	66 (46)	65 (93)	<0.0001*
Lopinavir/ritonavir	54 (25)	17 (12)	37 (53)	<0.0001*
Hydroxychloroquine/chloroquine	92 (43)	39 (27)	53 (76)	<0.0001*
Tocilizumab	7 (3)	1 (1)	6 (9)	0.006***
Outcomes (at end of follow-up)				
Discharged, n (%)	161 (69)	124 (87)	37 (53)	<0.0001 *
Death in hospital, n (%)	51 (23)	18 (13)	33 (47)	
Still hospitalised, n (%)	1 (0,5)	1 (1)	0 (0)	

439 Data are median and interquartile range (IQR) or numbers (%). * χ^2 -test, **Mann-Whitney U test,
440 ***Fisher's exact test.

441 ICU, intensive care unit; BMI, body mass index; COPD, chronic obstructive pulmonary disease.

442

443 **Table 2:** Management and complications of 70 ICU patients with COVID-19

Characteristics of ICU patients	All patients n=70	Survivors n=37	Non- Survivors n=33	p-value
Age	64.5 (59-76)	61 (54-70)	70 (61-78)	0.01**
Direct ICU referrals	27 (39)	16 (43)	11 (33)	0,40*
Blood type O	15/65 (23)	9/33 (27)	6/32 (19)	0.41*
Blood type A	38/65 (59)	20/33 (61)	18/32 (56)	0.72*
Disease severity upon ICU admission				
SAPS2-score (d1)	46 (40-52)	45 (31-50)	49 (45-55)	0,005**
No ARDS or mild ARDS	6 (9)	4 (11)	2 (6)	0,09*
Moderate ARDS	27 (39)	18 (49)	9 (27)	
Severe ARDS	37 (53)	15 (41)	22 (67)	
Horovitz-Index (lowest in first 24h after ICU admission)	110 (82-126)	114 (88-137)	96 (79-116)	0,13**
ICU Management				
High-flow nasal cannula	30 (43)	20 (54)	10 (30)	0,05*
Non-invasive mechanical ventilation	30 (43)	15 (41)	15 (46)	0,68*
High-flow nasal cannula or non-invasive mechanical ventilation (and no invasive mechanical ventilation)	6 (9)	5 (14)	1 (3)	0,20***
Invasive mechanical ventilation	57 (81)	28 (76)	29 (88)	0,23***
Median length of invasive mechanical ventilation, days	17 (8-32)	19.5 (9-40)	15 (7-22)	0,13**
Tracheostomy	26 (37)	17 (46)	9 (27)	0,11*
ECMO	23 (33)	9 (24)	14 (42)	0,11*
Length of ECMO treatment, days	11 (7-21)	9 (8-23)	12 (4-22)	0,79**
ECMO cannulation in external hospital	9/23 (39)	3/9 (33)	6/14 (43)	>0,999***
ECMO weaning successful	12/23 (52)	9/9 (100)	3/14 (21)	0,0003***
Veno-arterial ECMO or left ventricular unloading (Impella®)	4/23 (17)	0	4/14 (29)	0,13***
Prone-positioning	43 (61)	21 (57)	22 (67)	0,40*
Number of prone-positionings per patient	9 (5-13)	8.5 (5-13)	9.0 (6-14)	0,85**
Prone-positioning during ECMO	19/23 (83)	8/9 (89)	11/14 (79)	>0,999***
Repeated neuromuscular blockade	11 (16)	4 (11)	7 (21)	0,33***
Inhaled nitric oxide	6 (9)	4 (11)	2 (6)	0,68***
Complications				
Pulmonary embolism (CT-verified)	16 (23)	10 (27)	6 (18)	0,38*
Central pulmonary embolism	5/16 (31)	3/10 (30)	2/6 (33)	>0,999***
Segmental/subsegmental pulmonary embolism	16/16 (100)	10/10 (100)	6/6 (100)	>0,999***
Acute kidney injury with need of renal	26 (37)	12 (32)	14 (42)	0,39*

replacement therapy				
Replacement of renal replacement system due to thrombosis (at least once)	11/26 (42)	6/12 (42)	5/14 (50)	0,46*
ECMO system or ECMO pump replacement system due to thrombosis (at least once)	12/23 (52)	5/9 (56)	7/14 (50)	>0,999***
Intracerebral bleeding (CT-verified)	11 (16)	5 (11)	6 (16)	0,59*
Intracerebral bleeding w/o ECMO	6/47 (13)	3/28 (11)	3/19 (18)	0,67***
Ischemic stroke	9 (13)	3 (8)	6 (11)	0,29***
Ischemic stroke w/o ECMO	4/47 (9)	2/28 (7)	2/19 (11)	>0,999***
Cardiac arrest with ROSC	6 (9)	1 (3)	5 (15)	0,09***
Pulmonary bleeding	8 (11)	3 (8)	5 (15)	0,46***
Pneumothorax	12 (17)	5 (14)	7 (21)	0,39*
Septic shock	43 (61)	17 (46)	26 (79)	0,005*
Cardiogenic shock	13 (19)	5 (14)	8 (24)	0,25*
Hemorrhagic shock	9 (13)	4 (11)	5 (15)	0,73***
Pulmonary bacterial superinfection†	26 (37)	15 (41)	11 (33)	0,53*
Positive blood cultures	28 (40)	18 (49)	10 (30)	0,12*
Positive blood cultures (without typical contaminants of skin flora)	16 (23)	9 (24)	7 (21)	0,76*
Aspergillus positive respiratory samples with initiation of antifungal therapy	6 (9)	1 (3)	5 (15)	0,09***

444 Data are median and interquartile range (IQR) or numbers (%). * χ^2 -test, **Mann-Whitney U test,
445 ***Fisher's exact test.

446 ICU, intensive care unit; ARDS, acute respiratory distress syndrome; CT, computed tomography scan

447 † Positive respiratory samples with *Staphylococcus aureus*, *Streptococcus pneumoniae* or Gram-
448 negative bacteria (*Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Proteus*
449 *mirabilis*, *Enterobacter cloacae*, *Citrobacter freundii*, *Serratia marcescens*) with initiation of
450 antibacterial treatment

451

452

453 **Table 3:** Multivariable Cox regression analysis

Model/Analysis	Multivariable Cox regression					
Endpoint	Discharge			Death		
Variable	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Sex male ¹	0.68	0.50-0.94	0.020	1.37	0.74-2.54	0.310
Age 65-74 years ²	0.63	0.37-1.06	0.079	3.45	1.49-7.98	0.004
Age ≥ 75 years ²	0.71	0.49-1.02	0.067	3.56	1.74-7.30	0.001
Hospital-acquired COVID-19 ³	0.73	0.48-1.12	0.155	0.91	0.45-1.84	0.790
Comorbidities present (≥1) ⁴	0.87	0.60-1.25	0.442	1.30	0.61-2.79	0.494
Length of stay ⁵	1.00	0.99-1.01	0.739	0.98	0.94-1.02	0.372
Model/Analysis	Fine and Gray model					
Endpoint				Death		
Variable				Subdistribution hazard ratio	95% CI	p-value
Sex male ¹				1.90	1.04-3.48	0.03
Age 65-74 years ²				4.16	1.82-9.49	<0.001
Age ≥ 75 years ²				4.13	2.05-8.32	<0.001
Hospital-acquired COVID-19 ³				1.18	0.60-2.34	0.59
Comorbidities present (≥1) ⁴				1.25	0.59-2.68	0.55
Length of stay ⁵				0.98	0.94-1.03	0.23

454 ¹ Reference: female, ² reference: age 0-64 years, ³ reference: community-acquired COVID-19,
455 ⁴ reference: no comorbid condition, ⁵ reference: 0 days (Previous length of stay was the time from
456 hospital admission to COVID-19 onset, for patients with community acquired COVID-19, the length of
457 stay was 0 days).

458

459

460

461

Table 4: Critical terminal organ failure and modes of death in 51 patients with COVID-19

Parameter	Patients who died n=51	Patients who died Non-ICU care n=18	Patients who died ICU care n=33	p-value*
Predominant terminal organ failure during dying process				
Septic shock	21 (41)	0	21 (63)	0.001
Multiorgan failure (n>=2)	35 (69)	6 (33)	29 (88)	0.001
Failure of 2 organs	9 (18)	4 (22)	5 (15)	0.03**
Failure of 3-4 organs	16 (31)	2 (11)	14 (42)	
Failure of >4 organs	10 (20)	0	10 (30)	
Lung failure	49 (96)	17 (94)	32 (97)	>0,999
IMV and ECMO used	14 (28)	0	14 (42)	<0.0001
IMV used, no ECMO used	16 (31)	1 (6)	15 (46)	
No IMV, no ECMO used	19 (37)	16 (89)	3 (9)	
Heart failure	15 (29)	1 (6)	14 (42)	0.009
Kidney injury	27 (53)	3 (17)	24 (73)	0.0003
Gastro-intestinal injury	13 (26)	0	13 (39)	0.002
Liver failure	9 (18)	1 (6)	8 (24)	0.13
Brain injury any	20 (39)	3 (17)	17 (52)	0.02
Intracerebral hemorrhage	5 (10)	0	5 (16)	0.15
Thrombembolic event and non-cerebral hemorrhage	11 (22)	0	11 (33)	0.005
Cardiogenic shock	7 (14)	0	7 (21)	0.04
Cardiac arrest - CPR w/o ROSC	5 (10)	1 (6)	4 (12)	0.64
Life support in dying process				
Withholding of ICU	17 (33)	17 (94)	0	<0.0001**
Initial ICU therapy, withdrawal in worsening condition	18 (35)	0	18 (55)	
Full care	16 (31)	1 (6)	15 (46)	
Involvement of COVID-19 as jugdeg by two independent reviewers				
Death presumed due to COVID-19 in patients with normal life expectancy	16 (31)†	1 (6)	15 (46)	0.01**
Death presumed due to COVID-19 in patient with frailty/comorbidities	30 (59)	15 (83)	15 (46)	
Death presumed due other condition incl. frailty/comorbidities	5 (10)	2 (11)	3 (9)	

Data are numbers (%). *Fisher's exact test, except ** χ^2 -test.

† Mean years of potential life lost (YPLL) per patient (according to current average life expectancy) 13,1 years.

Figures

Figure 1 Stacked probability plot for the multistate model (overall cohort)

Fig. 1

469

Figure legend

471 Stacked probability plot for the multistate model. The plot is based on the complete dataset (n=213)
 472 and illustrates within a single graph the probabilities to be in a specific state over time as well as the
 473 expected average mean duration spent in each state. The probability to be on a regular ward, in the
 474 ICU, on mechanical ventilation (MV), on ECMO support, discharged alive or dead over the course of
 475 time corresponds to the distance between two curves. The area between two curves corresponds to
 476 the mean time spent in the specific states.

477

478

479

480 **Figure 2** Stacked probability plot for the multistate model stratified by the different starting
481 states/levels of care

Starting state	Average length of stay in specific state				Length of stay total	Probability to be discharged alive	Probability of death
	Reg. ward	ICU	MV	ECMO			
Regular ward	13.6 days	0.8 days	1.4 days	0.2 days	16.0 days	83%	16%
ICU (non-ventilated)	5.0 days	5.6 days	13.9 days	2.0 days	26.5 days	52%	47%
MV (mech. ventilation)	4.0 days	2.4 days	15.6 days	8.0 days	30.0 days	42%	57%

Fig. 2

482

483

484 **Figure legend**

485 **Figure 2**

486 Stacked probability plot for the multistate model stratified by the different starting states/levels of
487 care. Corresponding estimates of average length of stay in a specific state and probabilities to be
488 discharged alive or to die within 90 days after COVID-19 onset are given below the plot.

489

490 **Supplementary material**

491 **Supplementary Figure S1** COVID dynamic care model of the University Medical Center Freiburg

492 **Supplementary Figure S2** COVID response at the University Medical Center Freiburg

493 **Supplementary Figure S3** Schematic diagram of the applied multistate model

494 **Supplementary Figure S4** Cohort plot of 213 COVID-19 patients

495 **Supplementary Figure S5** Stacked probability plots for the multistate model stratified by age

496 **Supplementary Figure S6** Stacked probability plots for the multistate model stratified by sex

497 **Supplementary Figure S7** Stacked probability plots for the multistate model stratified by the
498 presence of comorbidities

499 **Supplementary Figure S8** Stacked probability plots for the multistate model stratified by the
500 presence of immunodeficiency

501 **Supplementary Figure S9** Stacked probability plots for the multistate model stratified by
502 presence of malignancy/neoplasm

503 **Supplementary Table** Overview on concordance in the review process concerning mode of
504 death

505

506 **Legends Supplementary Material**

507 **Supplementary Figure S1**

508 Patient flow in the dynamic care model established by the Task force Coronavirus (consisting of
509 representatives of the ID department, Emergency department, Virology and Infection control
510 Departments and the Pandemic Operational Committee of the University Medical Center Freiburg):
511 Patients from the outpatient setting or inter-hospital transfers were evaluated in dedicated areas in
512 the emergency department. Confirmed COVID patients were distributed according to severity of
513 disease on regular wards with or without monitoring. Patients with suspicion of COVID were
514 admitted to separate holding areas. Unstable patients, ICU transfers or admissions to the ECMO
515 facility were managed via the ICU coordinator and allocated to dedicated ICU and ECMO facilities.

516 The dynamic care model included an escalation strategy, in which additional regular wards and ICU
517 beds were equipped, physicians and nursing staff were trained and these wards were subsequently
518 recruited upon utilisation of a certain threshold of COVID bed capacities.

519 ID Infectious diseases, ICU Intensive care unit, IMC Intermediate care ward, COVID Coronavirus
520 Disease 2019.

521 **Supplementary Figure S2**

The measures implemented in the COVID-19 response, the evolution of the peak incidences in the region (COVID-19 cases/100.00/day [dates of registration at local health authorities]) and the corresponding number of admissions in the University Medical Center Freiburg.

Supplementary Figure S3

The six state model considers the events hospitalisation in 1) regular ward, 2) ICU, 3) mechanical ventilation (MV), 4) ECMO, 5) discharge and 6) death. The boxes represent the possible states a patient may encounter and the arrows represent the possible transitions from one state to another. Thus, the arrows between the states show which transitions are possible.

Supplementary Figure S4

Course of hospital stay of 213 COVID-19 hospitalised patients. The applied six state model considers the events hospitalisation (hospital, i.e. regular ward), ICU, mechanical ventilation (MV), ECMO, discharge and death.

Supplementary Figure S5:

Stacked probability plots for the multistate model stratified by age. The plots illustrates in more detail the results of the competing risks regression models (however, not adjusted for other covariates). The graphs visualises the differences in the expected average mean duration spent in each state and in the probabilities to be in one of the states between the risk groups.

Supplementary Figure S6:

Stacked probability plots for the multistate model stratified by sex. The plots illustrates in more detail the results of the competing risks regression models (however, not adjusted for other covariates). The graphs visualises the differences in the expected average mean duration spent in each state and in the probabilities to be in one of the states between the risk groups.

Supplementary Figure S7:

Stacked probability plots for the multistate model stratified by the presence of comorbidities. The plots illustrates in more detail the results of the competing risks regression models (however, not adjusted for other covariates). The graphs visualises the differences in the expected average mean duration spent in each state and in the probabilities to be in one of the states between the risk groups.

Supplementary Figure S8:

Stacked probability plots for the multistate model stratified by the presence of immunodeficiency. The plots illustrates in more detail the results of the competing risks regression models (however, not adjusted for other covariates). The graphs visualises the differences in the expected average mean duration spent in each state and in the probabilities to be in one of the states between the risk groups.

Supplementary Figure S9:

Stacked probability plots for the multistate model stratified by presence of malignancy/neoplasm. The plots illustrates in more detail the results of the competing risks regression models (however,

559 not adjusted for other covariates). The graphs visualises the differences in the expected average
560 mean duration spent in each state and in the probabilities to be in one of the states between the risk
561 groups.

562 **Supplementary Table**

563 Overview on concordance in the review process concerning mode of death.

564

565

566

Suppl. Fig. S1

Suppl. Fig. S2

Suppl. Fig. S3

Suppl. Fig. S4

Suppl. Fig. S5

Female (n=84)

Male (n=129)

Days Since Hospitalization and COVID-19 Diagnosis

Days Since Hospitalization and COVID-19 Diagnosis

Suppl. Fig. S7

No Primary or secondary immunodeficiency
incl. immunosuppressive medication (n=187)

Primary or secondary immunodeficiency
incl. immunosuppressive medication (n=26)

Days Since Hospitalization and COVID-19 Diagnosis

Days Since Hospitalization and COVID-19 Diagnosis

Suppl. Fig. S9

Mode of Death	Lung failure and ECMO support	Lung failure and invasive MV (w/o ECMO)	Lung failure (w/o ECMO or MV)	heart failure	Kidney injury	Gastro intestinal failure
discordance	0	3	0	10	4	5
concordance	0	48	51	41	47	46
% concordance after second review	100	94	100	80	92	90

Mode of Death	Liver failure	Brain injury	Thrombembolic event and non-cerebral hemorrhage	Septic shock	Cardiogenic shock	CPR w/o ROSC
discordance	6	5	3	6	4	3
concordance	45	46	48	45	47	48
% concordance after second review	88	90	94	88	92	94

Mode of Death	Withholding of ICU	Withdrawal of ICU therapy	Full care	Death presumed to COVID-19 in patients with normal life expectancy	Death presumed due to COVID-19 in patient with frailty/comorbidities	Death presumed due to other condition incl. frailty/comorbidities
discordance	0	17	11	7	14	8
concordance	51	34	40	44	37	43
% concordance after second review	100	67	78	86	73	84

Supplementary Table